ライフサイエンスコーパス: end-stage renal disease

1 le PH1 was diagnosed in 56 patients (17 with end-stage renal disease).

2 es leads to chronic kidney disease ending in end stage renal disease.

3 te phase and an increased risk of developing End Stage Renal Disease.

4 option for patients with type 1 diabetes and end stage renal disease.

5 as been acknowledged as the best therapy for end-stage renal disease.

6 e of a reduced risk of future progression to end-stage renal disease.

7 isease patients, including patients with non-end-stage renal disease.

8 discharge, ICU stay less than 24 hours, and end-stage renal disease.

9 is the preferred treatment for patients with end-stage renal disease.

10 ey disease, eGFR decline of 30% or more, and end-stage renal disease.

11 nt chronic kidney disease, eGFR decline, and end-stage renal disease.

12 splantation is a lifesaving intervention for end-stage renal disease.

13 han 190 cm, obesity, and a family history of end-stage renal disease.

14 epithelial cells will lead progressively to end-stage renal disease.

15 tic Nephropathy (DN) is the leading cause of end-stage renal disease.

16 We enrolled adults with end-stage renal disease.

17 ially provider continuity, for patients with end-stage renal disease.

18 ng kidney donors are at an increased risk of end-stage renal disease.

19 fluid-filled kidney cysts and progression to end-stage renal disease.

20 eatment of choice for patients with terminal end-stage renal disease.

21 Few studies have focused on patients with end-stage renal disease.

22 ause of pediatric chronic kidney disease and end-stage renal disease.

23 r preventing progression of the condition to end-stage renal disease.

24 f death, de novo chronic kidney disease, and end-stage renal disease.

25 in heart rhythm complexity in patients with end-stage renal disease.

26 combined phenotype of severe retinopathy and end-stage renal disease.

27 and promotes the development of chronic and end-stage renal disease.

28 at the last follow-up; no patient developed end-stage renal disease.

29 in patients with chronic kidney disease and end-stage renal disease.

30 transplantation early after the diagnosis of end-stage renal disease.

31 glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

32 ted with an increased risk of posttransplant end-stage renal disease.

33 n increase serum hsCRP levels in adults with end-stage renal disease.

34 Ab-induced, self-limiting nephritis to fatal end-stage renal disease.

35 efits of using that organ for a patient with end-stage renal disease.

36 e and functioning of the kidneys, leading to end-stage renal disease.

37 observation unit, previous randomisation, or end-stage renal disease.

38 reting myofibroblasts, ultimately leading to end-stage renal disease.

39 Glomerulonephritis is a common cause of end-stage renal disease.

40 enefits outweigh the risks of these drugs in end-stage renal disease.

41 omplication of diabetes and a major cause of end-stage renal disease.

42 nd acceleration of chronic kidney disease to end-stage renal disease.

43 ) but not in rates of amputation, stroke, or end-stage renal disease.

44 of hydroxyurea as preventative measures for end-stage renal disease.

45 sits, hospitalizations, quality of life, and end-stage renal disease.

46 rs reduced heart failure hospitalization and end-stage renal disease.

47 sease and a requisite for the development of end-stage renal disease.

48 c disorders and the leading genetic cause of end-stage renal disease.

49 ephropathy (DN) remains the leading cause of end-stage renal disease.

50 atient developed a TMA due to CD and reached end-stage renal disease.

51 ial infarction, end-stage liver disease, and end-stage renal disease.

52 erulosclerosis, a condition that can lead to end-stage renal disease.

53 rom ethylene glycol poisoning, can result in end-stage renal disease.

54 disease-related hospitalization or death, or end-stage renal disease.

55 lar lesions, with inescapable progression to end-stage renal disease.

56 could improve care and retard progression to end-stage renal disease.

57 , that was associated with a 10-year risk of end-stage renal disease.

58 d prompt treatment to prevent progression to end-stage renal disease.

59 , respectively); the smallest decline was in end-stage renal disease (-28.3%; 95% CI, -34.6 to -21.6)

60 dds ratio [OR], 7.24; P = .015), and to have end-stage renal disease (33% vs 7%; OR, 7; P = .012).

61 e (8.9%) and all-cause mortality (8.7%) than end-stage renal disease (4.0%).

62 Six (0.2%) developed end-stage renal disease 5 to 17 years after donation, (2

63 States are required to educate patients with end-stage renal disease about all treatment options, inc

64 he incidences of lower-extremity amputation, end-stage renal disease, acute myocardial infarction, st

65 5% CI 1.19-1.26), and a 98% higher hazard of end-stage renal disease (adjusted hazard ratio = 1.98, 9

66 he best therapeutic option for patients with end-stage renal disease after orthotopic liver transplan

67 tion is associated with an increased risk of end-stage renal disease, although this outcome is uncomm

68 Given increased risk for end-stage renal disease among obese living donors, cente

69 g of 2,806 T2D case subjects with or without end-stage renal disease and 4,265 control subjects from

70 Secondary outcomes were end-stage renal disease and acute kidney injury.

71 Patients with end-stage renal disease and aortoiliac stenosis are ofte

72 nd are associated with an increased risk for end-stage renal disease and cardiovascular events.

73 vere cardiomyopathy that was associated with end-stage renal disease and characterized by severe func

74 abetes is the leading cause of blindness and end-stage renal disease and contributes to both microvas

75 nitive impairment is common in patients with end-stage renal disease and is associated with poor outc

76 ced chronic kidney disease, as patients with end-stage renal disease and kidney transplant recipients

77 ovel drug candidates to delay progression to end-stage renal disease and limit or abrogate cardiovasc

78 e obese at donation are at increased risk of end-stage renal disease and may benefit from intensive p

79 e significantly more patients suffering from end-stage renal disease and more patients listed for kid

80 on has transformed the life of patients with end-stage renal disease and other chronic kidney disorde

81 hrotic proteinuria and frequently results in end-stage renal disease and recurrence after kidney tran

82 odies, representing up to 30% of patients in end-stage renal disease and renal transplantation, is th

83 min/1.73 m(2) and 25% decrease in eGFR), (3) end-stage renal disease, and (4) rate of kidney function

84 urinary catheters, diabetes mellitus, AIDS, end-stage renal disease, and cirrhosis), need for intens

85 oke, coronary artery disease, heart failure, end-stage renal disease, and dementia.

86 acute kidney injury, chronic kidney disease, end-stage renal disease, and electrolyte abnormalities.

87 mportant aspect of the care of patients with end-stage renal disease, and phosphate binders are usual

88 iabetic nephropathy (DN) is a major cause of end-stage renal disease, and therapeutic options for pre

89 Patients with chronic kidney disease and end-stage renal disease are at 5- to 10-fold higher risk

90 ernative treatment options for patients with end-stage renal disease are being sought.

91 els are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals wit

92 nostic tests to identify subjects at risk of end-stage renal disease, as well as biomarkers to measur

93 Nine patients (42%) had end stage renal disease at a mean age of 10.6 years (6.5

94 ystem, we identified all adult patients with end-stage renal disease attributed to 1 of 6 GN subtypes

95 The number of patients with end-stage renal disease being relisted for a second kidn

96 aseline serum creatinine (MMKD-Study) and/or end stage renal disease (both studies).

97 patients undergoing peritoneal dialysis for end-stage renal disease but without cirrhosis were inclu

98 splantation is the best treatment option for end-stage renal disease, but allograft loss remains a si

99 panics (versus NHWs) in the first year after end-stage renal disease, but by Year 4, access to transp

100 0.5% of live births and are a major cause of end-stage renal disease, but their genetic aetiology is

101 Progression to end-stage renal disease can be slowed by appropriate med

102 he concentration of poverty appear to impact end-stage renal disease care and potentially access to t

103 erited nephropathy responsible for 4%-10% of end-stage renal disease cases.

104 ajor systemic underlying diseases, including end-stage renal disease, cholestatic liver disease, endo

105 ath (aORs from 2.4 to 3.8, p <0.05) included end-stage renal disease, coronary artery disease, and ne

106 reported using Risk, Injury, Failure, Loss, End-stage renal disease criteria, and independent factor

107 ng consensus Risk, Injury, Failure, Loss and End-Stage Renal Disease criteria.

108 [eGFR] to less than 60 mL/min per 1.73m(2), end-stage renal disease (defined as dialysis for at leas

109 ibute to the inflammatory process underlying end-stage renal disease development in both types of dia

110 Prevalence of African American ethnicity, end-stage renal disease, diabetes, fair/poor self-rated

111 than 0, public insurance or no insurance at end-stage renal disease diagnosis, more regional acute c

112 rdiovascular events or mortality) and renal (end-stage renal disease: dialysis, transplantation, and/

113 eatinine concentration and/or progression to end-stage renal disease) during follow-up in both cohort

114 y safety end point was a composite of death, end-stage renal disease, embolic events resulting in end

115 f AIDS, acute myocardial infarction, stroke, end-stage renal diseases, end-stage liver diseases, or d

116 The chronic kidney disease (CKD) or end stage renal disease (ESRD) is generally caused due t

117 with the other groups (P = 0.06) and time to end stage renal disease (ESRD) was longer in this group

118 kidney disease (CKD) to predict the risk of end stage renal disease (ESRD), i.e., the need for dialy

119 Outcomes included progression to end stage renal disease (ESRD), length of stay, and mort

120 are living longer, and 11%-18% will develop end stage renal disease (ESRD).

121 g risk and accounting for the progression to end-stage renal disease (ESRD) after discharge.

122 Kidney donors can develop end-stage renal disease (ESRD) after donation, but the o

123 We examined the association of incident end-stage renal disease (ESRD) after liver transplantati

124 of kidney function in predicting the risk of end-stage renal disease (ESRD) after PTA remains unclear

125 from living donors who subsequently develop end-stage renal disease (ESRD) also have higher graft fa

126 ion between achieved blood pressure (BP) and end-stage renal disease (ESRD) among patients with chron

127 s an independent predictor of posttransplant end-stage renal disease (ESRD) and mortality.

128 es address incidence of and risk factors for end-stage renal disease (ESRD) and proffer a new renal r

129 Patients with end-stage renal disease (ESRD) are characterized by incr

130 Obesity and end-stage renal disease (ESRD) are on the increase world

131 More than 80% of patients with end-stage renal disease (ESRD) are reported to have card

132 neurodegenerative processes in patients with end-stage renal disease (ESRD) compared to healthy contr

133 F) access improves survival in patients with end-stage renal disease (ESRD) compared with other modal

134 Patients with end-stage renal disease (ESRD) due to lupus nephritis (L

135 familial Mediterranean fever (FMF) who reach end-stage renal disease (ESRD) due to reactive amyloidos

136 idney transplant recipients with rare native end-stage renal disease (ESRD) etiologies.

137 association between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992)

138 ciated with the risk of rapid progression to end-stage renal disease (ESRD) in a cohort of proteinuri

139 -cause mortality, cardiovascular events, and end-stage renal disease (ESRD) in a large cohort of U.S.

140 d 1 in 1,000 people and slowly progresses to end-stage renal disease (ESRD) in about half of these in

141 Risk of end-stage renal disease (ESRD) in kidney donors has been

142 een AKI after CABG and the long-term risk of end-stage renal disease (ESRD) is unknown.

143 estimated 6500 undocumented immigrants with end-stage renal disease (ESRD) live in the United States

144 >=30% decline in eGFR (1.23, 1.15-1.33), and end-stage renal disease (ESRD) or >=50% decline in eGFR

145 The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascu

146 umented survival advantage for patients with end-stage renal disease (ESRD) over dialysis, regardless

147 compared with dialysis, nearly one third of end-stage renal disease (ESRD) patients are not educated

148 comes for end-stage liver disease (ESLD) and end-stage renal disease (ESRD) patients awaiting transpl

149 se underlying sociocultural factors preclude end-stage renal disease (ESRD) patients from initiating

150 protection of herpes zoster (HZ) vaccine in end-stage renal disease (ESRD) patients might be insuffi

151 ey transplant is the best treatment for most end-stage renal disease (ESRD) patients, but proportiona

152 ic malignancy incidence has been reported in end-stage renal disease (ESRD) patients, especially of f

153 etween hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) remains controversial wit

154 on between periodontal disease treatment and end-stage renal disease (ESRD) remains unclear.

155 Short studies that generate lifetime end-stage renal disease (ESRD) risks for young living ki

156 (COPD), asthma, diabetes mellitus (DM), and end-stage renal disease (ESRD) were calculated by Poisso

157 Participants with end-stage renal disease (ESRD) were excluded.

158 Infections are important complications of end-stage renal disease (ESRD) with few studies having i

159 In end-stage renal disease (ESRD), a condition characterize

160 ted diagnoses of myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining ca

161 of patients with CKD, especially those with end-stage renal disease (ESRD), are controversial.

162 ly those of black race, are at high-risk for end-stage renal disease (ESRD), but contributing factors

163 verall, 9%, 5%, and 8% of patients developed end-stage renal disease (ESRD), major cardiovascular eve

164 e relationship of BMI with macroalbuminuria, end-stage renal disease (ESRD), or DKD defined as presen

165 In patients with end-stage renal disease (ESRD), surgical aortic valve re

166 -onset disease that is an important cause of end-stage renal disease (ESRD), which requires transplan

167 ion rate (GFR) <60 mL/min/1.73 m(2) and with end-stage renal disease (ESRD), with HP 2-2 having great

168 ECR was associated with development of end-stage renal disease (ESRD).

169 es, have an increased risk of progression to end-stage renal disease (ESRD).

170 eficiency virus (HIV)-infected patients with end-stage renal disease (ESRD).

171 nsition from chronic kidney disease (CKD) to end-stage renal disease (ESRD).

172 nd treat AKI or impede progression to CKD or end-stage renal disease (ESRD).

173 on screening for individual risk factors for end-stage renal disease (ESRD).

174 in adults, and one-third of patients develop end-stage renal disease (ESRD).

175 r nephrectomy increases the risk of eventual end-stage renal disease (ESRD).

176 tients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

177 2 diabetes mellitus (DM) and progression to end-stage renal disease (ESRD).

178 e of death in children and young adults with end-stage renal disease (ESRD).

179 population and compare risk of mortality and end-stage renal disease (ESRD).

180 is associated with progression of DN toward end-stage renal disease (ESRD).

181 fibrillation (AF) is common in patients with end-stage renal disease (ESRD).

182 inflamed surface area (PISA) in adults with end-stage renal disease (ESRD).

183 investigate the association between HCM and end-stage renal disease (ESRD).

184 oning in a patient with multiple myeloma and end-stage renal disease (ESRD).

185 of genetic variants with IgA nephropathy and end-stage renal disease (ESRD, n = 100).

186 response (P < .009), most of whom developed end-stage renal disease (ESRD; P = .005).

187 modify the subsequent risk of progression to end-stage-renal disease (ESRD) or all-cause mortality (A

188 d diabetic nephropathy (macroalbuminuria and end-stage renal disease [ESRD]).

189 e endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creati

190 liver disease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older th

191 (sickle cell nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (r

192 incident, adult (18-69 years) patients with end-stage renal disease from 308 Georgia dialysis facili

193 In conclusion, although many patients with end stage renal disease have received transplants throug

194 d its application for replacement therapy in end-stage renal disease have been widely discussed.

195 isk" volume-sensitive populations, including end-stage renal disease, heart failure, obesity, advance

196 All outcome analyses controlled for sex, end-stage renal disease, heart failure, sepsis severity

197 e used (recipients' age, cause and length of end-stage renal disease, hemoglobin, albumin, selected c

198 prevalence of 6% to 40% among patients with end-stage renal disease, hepatitis C virus (HCV) infecti

199 s (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolera

200 Female sex, diabetic end-stage renal disease, history of a previous transplan

201 al admission, cancer hospital admission, and end-stage renal disease hospital admission) were identif

202 1]), male sex (HR, 1.21; 95% CI, 1.12-1.31), end-stage renal disease (HR, 1.66; 95% CI, 1.41-1.95), s

203 PPI use also associated with development of end-stage renal disease (HR, 2.40; 95% CI, 0.76-7.58) an

204 nce interval {CI}, 1.48-9.92]; P = .004) and end-stage renal disease (HR, 4.27 [95% CI, 1.89-9.11]; P

205 ng-term follow-up of donors has demonstrated end-stage renal disease in 0.6% at 25 years.

206 IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-

207 ey transplantation (KT) is the treatment for end-stage renal disease in appropriate HIV-positive indi

208 ases constitute the most important cause for end-stage renal disease in children and adolescents.

209 y result in chronic hyperoxaluria, promoting end-stage renal disease in children and young adults.

210 tulated to be involved in the development of end-stage renal disease in diabetes, but which specific

211 ease (ADPKD) constitutes the fourth cause of end-stage renal disease in Europe.

212 result of longer survival, the prevalence of end-stage renal disease in HIV is increasing.

213 itis, is the most common cause of hereditary end-stage renal disease in the first three decades of li

214 All patients with end-stage renal disease in the United States without pri

215 retrospective analysis of all patients with end-stage renal disease in the US Renal Data System who

216 exposure; adults with chronic liver disease, end-stage renal disease (including hemodialysis patients

217 ring immunosuppressive therapy, persons with end-stage renal disease (including hemodialysis patients

218 ng hemodialysis via fistula in patients with end-stage renal disease irrespective of race/ethnicity.

219 ering dialysate temperature in patients with end-stage renal disease is associated with a decrease in

220 s shortcoming on mortality for patients with end-stage renal disease is enormous.

221 Patient survival with end-stage renal disease is longer after kidney transplan

222 ase, chronic kidney disease progression, and end-stage renal disease is not clear.

223 -specific humoral responses in patients with end-stage renal disease is poorly documented.

224 wide increase in the number of patients with end-stage renal disease leads to a growing waiting list

225 ogression to lupus nephritis (LN)-associated end-stage renal disease (LN-ESRD) in African Americans.

226 fect burden, especially its association with end-stage renal disease, may be less than many have surm

227 han men were being treated with dialysis for end-stage renal disease merits detailed further study, a

228 gnitive Impairment and Imaging Correlates in End Stage Renal Disease, NCT01883349.

229 or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, an

230 e (odds ratio, 0.18; CI, 0.13-0.25), or with end-stage renal disease (odds ratio, 0.23; CI, 0.13-0.40

231 0 to 60, glomerular filtration rate <30, and end-stage renal disease on dialysis had a higher risk of

232 Patients with end-stage renal disease on hemodialysis (ESRD-HD) and ao

233 In the 243 matched pairs of patients with end-stage renal disease on hemodialysis, PCI was associa

234 A 74-year-old woman with end-stage renal disease on maintenance hemodialysis pres

235 In the human study, participants with end-stage renal disease on peritoneal dialysis (PD) unde

236 Year 5 in NHBs and Year 4 in Hispanics after end-stage renal disease onset.

237 poor with the majority of patients reaching end-stage renal disease or dying with little or no chanc

238 The risk of end-stage renal disease or renal death was lower in the

239 We excluded patients with end-stage renal disease or solid organ transplants becau

240 osite primary outcome was the time to death, end-stage renal disease, or a 50% reduction from the bas

241 tent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease.

242 estimated glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), th

243 ion is not associated with excess mortality, end-stage renal disease, or morbidity, in at least 10 ye

244 as a sustained doubling of serum creatinine, end-stage renal disease, or renal death.

245 ial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented

246 dial infarction, end-stage liver disease, or end-stage renal disease outcomes.

247 ial infarction, end-stage liver disease, and end-stage renal disease outcomes.

248 We retrospectively studied adult-HUS end-stage renal disease patients (n = 559) placed on the

249 e for peripheral B cells, in 101 consecutive end-stage renal disease patients admitted for transplant

250 monoclonal antibody tesidolumab (LFG316) in end-stage renal disease patients awaiting kidney transpl

251 ta System Medicare-linked data on waitlisted end-stage renal disease patients between 2005 and 2009 w

252 seful for detecting occult infection foci in end-stage renal disease patients undergoing MHD.

253 Sixty-seven consecutive end-stage renal disease patients underwent live-donor ro

254 erapy may be used to treat thyroid cancer in end-stage renal disease patients who undergo hemodialysi

255 is widely used in chronic kidney disease and end-stage renal disease patients with hyperphosphatemia.

256 transplantation is an attractive option for end-stage renal disease patients with type 1 diabetes.

257 mpatible living-donor kidney transplants for end-stage renal disease patients with willing but incomp

258 ever, limited research has been conducted on end-stage renal disease patients.

259 During the end-stage renal disease phase at the time of transplant,

260 d rivaroxaban use in the atrial fibrillation-end-stage renal disease population has steadily risen wh

261 End-stage renal disease (PR = 1.41; 95% CI: 1.21-1.63; P

262 enal transplant recipients with aHUS-related end-stage renal disease received eculizumab: 10 from day

263 idney disease, doubling of serum creatinine, end-stage renal disease, renal transplant, or renal deat

264 ette smoking, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to

265 ette smoking, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to

266 lop chronic kidney disease, and some develop end-stage renal disease, requiring renal replacement the

267 A 50-year-old woman with end-stage renal disease secondary to autosomal dominant

268 ts with non-infantile disease (11%, all with end-stage renal disease) showed mild, likely PH1-related

269 In HNF1B patients who reach end-stage renal disease, single kidney transplantation (

270 In patients with both type 1 diabetes and end-stage renal disease, SPK recipients had similar prog

271 ors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease Study.

272 e observational ISAR (Risk Stratification in End-Stage Renal Disease) study, data on dynamic retinal

273 orbidity, kidney function) and completed the end-stage renal disease symptom checklist (perceived sid

274 and medical (CKD-EPI) data and completed the End-Stage Renal Disease Symptom Checklist (perceived sid

275 ection are at higher risk for progression to end-stage renal disease than those who have chronic kidn

276 In patients with end-stage renal disease, the prevalence of acquired risk

277 .e., older than 65 years of age), such as in end-stage renal disease, this therapy has not been optim

278 In most patients who develop end-stage renal disease, transplantation is the renal re

279 from the ongoing Time to Reduce Mortality in End Stage Renal Disease Trial, a large cluster-randomize

280 n: mixed cryoglobulinemia, chronic kidney or end-stage renal disease, type 2 diabetes, B-cell lymphom

281 treatment, and outcomes of individuals with end-stage renal disease undergoing dialysis might reveal

282 In patients with end-stage renal disease undergoing hemodialysis, it was

283 Patients with end-stage renal disease undergoing maintenance hemodialy

284 Patients with end-stage renal disease use the emergency department (ED

285 An increased risk of end-stage renal disease was associated with an IQR incre

286 In up to 15 years, follow-up end-stage renal disease was observed in 1 LD versus 7 TH

287 olled human immunodeficiency virus (HIV) and end-stage renal disease was on the kidney transplant wai

288 However, compared with placebo, end-stage renal disease was significantly less likely af

289 lization, device explant, and progression to end-stage renal disease were assessed using Fine-Gray mo

290 l outcomes (doubling of serum creatinine and end-stage renal disease) when used as an adjunct to angi

291 For patients with end-stage renal disease who are not candidates for fistu

292 Patients with end-stage renal disease who are undergoing dialysis are

293 ohort design on 29,095 elderly patients with end-stage renal disease who died between 2005 and 2013.

294 onic kidney disease, particularly those with end-stage renal disease who require dialysis and/or kidn

295 ta suggest that morbidly obese patients with end-stage renal disease who undergo LSG to improve trans

296 years or younger without preoperative AKI or end-stage renal disease who were undergoing cardiac surg

297 Most patients with end-stage renal disease will develop hyperparathyroidism

298 ving kidney donors have an increased risk of end-stage renal disease, with hypertension and diabetes

299 betic nephropathy (DN) is the major cause of end-stage renal disease worldwide.

300 ohorts, and three pharmacokinetic studies in end-stage renal disease, yielding a very low quality of